PHARMACEUTICAL AQUEOUS FORMULATION COMPRISING-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1 -YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1

,3,5-TRIAZIN-2-YL)PHENYL]UREA

The present invention relates to a pharmaceutical formulation comprising 1 - (4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl- 1 ,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable alkanesulphonate salt thereof. More specifically, the present invention relates to a pharmaceutical aqueous formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable alkanesulphonate salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral

administration to a patient.

1 -(4-{[4-(Dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin- 4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, and preparations thereof, are disclosed in

WO2009/143313. The compound is an inhibitor of PI3 kinase and mTOR that is useful for the treatment of cancer.

A crystalline form of 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3- [4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, and process for the

preparation thereof, are disclosed in WO2010/096619.

WO2016/097949 describes a pharmaceutical aqueous solution formulation suitable for intravenous administration comprising (i) 1 -(4-{[4-

(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea, or a lactate salt thereof, lactic acid and water, wherein 1 - (4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl- 1 ,3,5-triazin-2-yl)phenyl]urea is present at a solution concentration of less than 6mg/ml and sufficient lactic acid is present to provide a clear solution; or (ii) 1 -(4-{[4- (dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea, or a phosphate salt thereof, orthophosphoric acid and water, wherein 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6- dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea is present at a solution concentration of less than 4mg/ml and sufficient orthophosphoric acid is present to provide a clear solution. Lyophilisation of such formulations are also described. Of the many acids tested (i.e. citric acid, succinic acid, acetic acid, glycine, tartaric acid, maleic acid, malic acid, hydrochloric acid, lactic acid and orthophosphoric acid), only lactic acid and orthophosphoric acid are found to be capable of achieving a clear solution with a concentration of 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6- dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea of 3mg/ml or above.

1 -(4-{[4-(Dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin- 4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, also known as gedatolisib, has the chemical structure:

1 -(4-{[4-(dimethylamino)piperidin-1 -yl]

carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl- 1 ,3,5-triazin-2-yl)phenyl]urea

1 -(4-{[4-(Dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin- 4-yl-1 ,3,5-triazin-2-yl)phenyl]urea may be prepared in crystalline form and is chemically and physically stable at 25°C and 60% Relative Humidity (RH) for up to 3 years in this form. However, this free base is insufficiently water soluble to allow the preparation of an aqueous solution formulation suitable for intravenous or parenteral administration at the therapeutic dosage levels required.

There is a need to develop a pharmaceutically acceptable aqueous solution formulation of 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6- dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea that is (a) chemically stable on storage (e.g. at 25°C and 60% RH), (b) that will facilitate effective intravenous (or parenteral) administration of the drug to a mammal, including a human being, and (c) , preferably, to achieve a solution concentration of 1 -(4-{[4- (dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorph

triazin-2-yl)phenyl]urea that is at least 6mg/ml.

A solution concentration of 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea that is at least 6mg/ml is desirable to allow dose administration to subjects using a single vial presentation of the commercial drug product. A lyophilised drug product (for reconstitution) containing less than 6 mg/ml drug product solution will require multiple vials to deliver the required therapeutic dose. A multiple vial approach to dose delivery is not desirable given current regulatory expectations for these product types.

Preferably, the formulation is suitable for intravenous or parenteral

administration of 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6- dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea in view of the particular

pharmacokinetic and bioavailability characteristics of this drug.

It is essential that an intravenous formulation of any drug is a solution to facilitate safe and effective administration to a patient. It must be particle-free, and not form a gel or suspension. A clear, aqueous solution is preferred.

A "clear solution" is defined herein as a visually clear solution, which may bear a solution opalescence, that is essentially free from any visible particulates that can be observed on a visual inspection. Generally, if any particulate matter is observed, the formulation is not suitable for intravenous administration and should not be utilised as occlusion of blood vessels may occur. Accordingly, in view of the qualitative nature of the visual test, the term "essentially free from any visible particulates" is usually applied when no visible particulate matter is observed.

Particulate matter may be defined as follows:

• speck - discrete particle whose shape cannot be determined without

magnification

• smoke or swirl - fine particles that look like smoke or a tornado and usually originate from the sample vial floor and twist upward as the vial is swirled · flocculent material - loosely aggregated particles or soft flakes • particulates with a definite shape or characteristic can be described as glasslike, metallic-looking, etc.

The visual inspection can be conducted in accordance with the method defined in European Pharmacopoeia Method 2.9.20 entitled " Particulate

contamination: visible particles". This method determines particulate contamination of injections and infusions by extraneous, mobile, undissolved particles, other than gas bubbles, that may be present in the solutions. The test is intended to provide a simple procedure for the visual assessment of the quality of parenteral solutions as regards visible particles.

In European Pharmacopoeia Method 2.9.20 the apparatus (see

"Figure 2.9.20.-1" shown in Figure 3) consists of a viewing station comprising:

• a matt black panel of appropriate size held in a vertical position

• a non-glare white panel of appropriate size held in a vertical position next to the black panel

· an adjustable lampholder fitted with a suitable, shaded, white-light source and with a suitable light diffuser (a viewing illuminator containing two 13 Watt fluorescent tubes, each 525 mm in length, is suitable). The intensity of illumination at the viewing point is maintained between 2000 lux and 3750 lux, although higher values are preferable for coloured glass and plastic containers. The Method states: "Remove any adherent labels from the container and wash and dry the outside. Gently swirl or invert the container, ensuring that air bubbles are not introduced, and observe for about 5 seconds in front of the white panel. Repeat the procedure in front of the black panel. Record the presence of any particles." A suitable method in accordance with European Pharmacopoeia Method 2.9.20 that has been used for the present invention is described in Example 1 (i).

Other validated methods may be also be used for the dermination of if any visible particulates are present. Such methods include Optical Polarised Microscopy ("OPM"). A suitable OPM method that has been used for the present invention is described in Example 1 (H).

The present invention relates to a pharmaceutical aqueous formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6- dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, or a methanesulphonate or ethanesulphonate salt thereof, methanesulphonic acid or ethanesulphonic acid, and, optionally, a pharmaceutically acceptable beta- or gamma-cyclodextrin, that is a clear solution (hereafter "the formulation of the invention").

Preferably, methanesulphonic acid (and methanesulphonate salts) are used in the formulations of the invention.

In an embodiment of the invention is provided a pharmaceutical aqueous solution formulation comprising (a) 1-(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, or a methanesulphonate salt thereof, methanesulphonic acid and water, wherein 1-(4- {[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea is present at a solution concentration of less than 35mg/ml or up to 30mg/ml and sufficient methanesulphonic acid is present to provide a clear solution; or (b) 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6- dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, or an ethanesulphonate salt thereof, ethanesulphonic acid and water, wherein 1-(4-{[4-(dimethylamino)piperidin-1- yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea is present at a solution concentration of less than 35mg/ml or up to 30mg/ml and sufficient ethanesulphonic acid is present to provide a clear solution.

In an embodiment of the invention is provided a pharmaceutical aqueous solution formulation comprising (a) 1-(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, or a methanesulphonate salt thereof, methanesulphonic acid and water, wherein 1 -(4- {[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea is present at a solution concentration of from 6 to 30mg/ml and sufficient methanesulphonic acid is present to provide a clear solution; or (b) 1 - (4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl- 1 ,3,5-triazin-2-yl)phenyl]urea, or an ethanesulphonate salt thereof, ethanesulphonic acid and water, wherein 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3- [4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea is present at a solution concentration of from 6 to 30mg/ml and sufficient ethanesulphonic acid is present to provide a clear solution.

The "solution concentration" values referred to herein relate to the

concentration of the free base of 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea in the formulation of the invention.

It has been found that the use of methanesulphonic acid and ethanesulphonic acid enables a solution concentration of up to 30mg/ml of 1 -(4-{[4- (dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea to be achieved for a pharmaceutical aqueous solution formulation that is suitable for intravenous or parenteral administration to a patient, i.e. a clear, essentially particle-free solution. Such formulations may have an opalescent hue but they are still essentially particle-free.

Without being bound by theory, the opalescent hue may be caused by chromonic liquid crystal formation. Chromonic liquid crystals are formed by the formation of pi-pi stacked aromatic sections of a molecule forming column like stacks of dimers, trimers and low molecular weight oligomers of the molecules. The stacks that form can be shown via OPM to be non-crystalline microstructures associated to a chromonic liquid crystal. The non-crystalline microstructures exhibit interactions that are not permanent and there is movement to maintain the system in a free energy equilibrium. The opalescence of the solution comes from the alteration of the refractive index of the solution due to the formation of these stacks. OPM

micrographs of the solutions will show that there is no crystalline material present and instead there is a chromonic liquid crystal phase. The presence of a liquid crystal phase results in a solution with opacity and/or opalescence due to a difference in refractive index within the solution formed. For a discussion on liquid crystal formation see "Optical Properties of Condensed Matter and Applications", Jai Singh (Editor), ISBN: 978-0-470-02193-4, Wiley, October 2006.

Such a formulation can be directly administered to the patient (in order to avoid degradation occurring), intravenously or parenterally, preferably with the addition of a tonicity modifier. Alternatively, for administration to a patient at a later date, such a formulation, optionally containing a bulking agent and/or tonicity modifier, may be first freeze-dried to prepare a lyophilised solid composition that is chemically stable on storage for preferably at least 2 years, and which lyophilised solid composition then can be constituted, or reconstituted, to provide a clear aqueous solution, preferably with the addition of a tonicity modifier, as necessary, immediately prior to administration to a patient by the intravenous (or parenteral) route. The reconstituted or constituted solution may be added to an infusion bag prior to administration to a patient.

In respect of the formulations comprising methanesulphonic acid, it has been found that above a solution concentration of 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea of 35mg/ml or above, the necessary clear solutions at the pH required for intravenous administration to a patient are not obtained, or are not obtained consistently.

In respect of the formulations comprising ethanesulphonic acid, it has been found that above a solution concentration of 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea of above 35mg/ml or above, the necessary clear solutions at the pH required for intravenous administration to a patient are not obtained, or are not obtained consistently.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, methanesulphonic acid and water, wherein 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea is present at a solution concentration of less than 35mg/ml or up to 30mg/ml and sufficient methanesulphonic acid is present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea methanesulphonate, methanesulphonic acid and water, wherein 1 -(4-{[4- (dimethylamino)piperidin-l -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea is present at a solution concentration of less than 35mg/ml or up to 30mg/ml and sufficient methanesulphonic acid is present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, methanesulphonic acid and water, wherein 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea is present at a solution concentration of from 6 to 30mg/ml and sufficient

methanesulphonic acid is present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea methanesulphonate, methanesulphonic acid and water, wherein 1 -(4-{[4- (dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea is present at a solution concentration of from 6 to 30mg/ml and sufficient methanesulphonic acid is present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, methanesulphonic acid and water, wherein 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea is present at a solution concentration of from 6 to 22mg/ml and sufficient

methanesulphonic acid is present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea methanesulphonate, methanesulphonic acid and water, wherein 1 -(4-{[4- (dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea is present at a solution concentration of from 6 to 22mg/ml and sufficient methanesulphonic acid is present to provide a clear solution. One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, methanesulphonic acid and water, wherein 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea is present at a solution concentration of from 8 to 30mg/ml, from 10 to 30mg/ml, from 8 to 22mg/ml, from 10 to 22mg/ml, from 15 to 22mg/ml, from 6 to 25mg/ml or from 10 to 25mg/ml, and sufficient methanesulphonic acid is present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea methanesulphonate, methanesulphonic acid and water, wherein 1 -(4-{[4- (dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea is present at a solution concentration of from 8 to 30mg/ml, from 10 to 30mg/ml, from 8 to 22mg/ml, from 10 to 22mg/ml, from 15 to 22mg/ml, from 6 to 25mg/ml or from 10 to 25mg/ml, and sufficient methanesulphonic acid is present to provide a clear solution.

One embodiment of the formulation of the invention provides a

pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-

(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea, ethanesulphonic acid and water, wherein 1 -(4-{[4- (dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea is present at a solution concentration of less than 35mg/ml or up to 30mg/ml and sufficient ethanesulphonic acid is present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea ethanesulphonate, ethanesulphonic acid and water, wherein 1 -(4-{[4-

(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea is present at a solution concentration of less than 35mg/ml or up to 30mg/ml and sufficient ethanesulphonic acid is present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, ethanesulphonic acid and water, wherein 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea is present at a solution concentration of from 6 to 30mg/ml and sufficient

ethanesulphonic acid is present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea ethanesulphonate, ethanesulphonic acid and water, wherein 1 -(4-{[4- (dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea is present at a solution concentration of from 6 to 30mg/ml and sufficient ethanesulphonic acid is present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, ethanesulphonic acid and water, wherein 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea is present at a solution concentration of from 6 to 22mg/ml and sufficient

ethanesulphonic acid is present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea ethanesulphonate, ethanesulphonic acid and water, wherein 1 -(4-{[4- (dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea is present at a solution concentration of from 6 to 22mg/ml and sufficient ethanesulphonic acid is present to provide a clear solution. One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, ethanesulphonic acid and water, wherein 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea is present at a solution concentration of from 8 to 30mg/ml, from 10 to 30mg/ml, from 8 to 22mg/ml, from 10 to 22mg/ml, from 15 to 22mg/ml, from 6 to 25mg/ml or from 10 to 25mg/ml, and sufficient ethanesulphonic acid is present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea ethanesulphonate, ethanesulphonic acid and water, wherein 1 -(4-{[4- (dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea is present at a solution concentration of from 8 to 30mg/ml, from 10 to 30mg/ml, from 8 to 22mg/ml, from 10 to 22mg/ml, from 15 to 22mg/ml, from 6 to 25mg/ml or from 10 to 25mg/ml, and sufficient ethanesulphonic acid is present to provide a clear solution. A further embodiment of the formulation of the invention may optionally additionally comprise a pharmaceutically acceptable beta- or gamma-cyclodextrin. Examples of such a pharmaceutically acceptable beta-cyclodextrin are 2- hydroxypropyl-beta-cyclodextrin and sulphobutylether-p-cyclodextrin (SBECD). Examples of such a pharmaceutically acceptable gamma-cyclodextrin are gamma- cyclodextrin and 2-hydroxypropyl-gamma-cyclodextrin. Preferably, hydroxypropyl- beta-cyclodextrin is used in the formulations of the invention. By use of a

pharmaceutically acceptable beta- or gamma-cyclodextrin it has been found that clear solutions may be achieved with no opalescence and/or containing higher concentrations of 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6- dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea. One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, methanesulphonic acid, 2-hydroxypropyl-beta-cyclodextrin and water, wherein 1 -(4- {[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea is present at a solution concentration of less than 55mg/ml or up to 50mg/ml and sufficient methanesulphonic acid and 2-hydroxypropyl-beta- cyclodextrin are present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea methanesulphonate, methanesulphonic acid, 2-hydroxypropyl-beta-cyclodextrin and water, wherein 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6- dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea is present at a solution concentration of less than 55mg/ml or up to 50mg/ml and sufficient methanesulphonic acid and 2- hydroxypropyl-beta-cyclodextrin are present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, methanesulphonic acid, 2-hydroxypropyl-beta-cyclodextrin and water, wherein 1 -(4- {[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea is present at a solution concentration of up to 45mg/ml, up to 40mg/ml, up to 35mg/ml, up to 30mg/ml, from 6 to 50mg/ml, from 6 to 30mg/ml, from 8 to 30mg/ml, from 10 to 35mg/ml, from 10 to 30mg/ml, from 8 to 22mg/ml, from 10 to 22mg/ml, from 15 to 22mg/ml, from 10 to 20mg/ml, from 6 to 25mg/ml or from 10 to 25mg/ml and sufficient methanesulphonic acid and 2-hydroxypropyl-beta- cyclodextrin are present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea methanesulphonate, methanesulphonic acid, 2-hydroxypropyl-beta-cyclodextrin and water, wherein 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6- dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea is present at a solution concentration of up to 45mg/ml, up to 40mg/ml, up to 35mg/ml, up to 30mg/ml, from 6 to 50mg/ml, from 6 to 30mg/ml, from 8 to 30mg/ml, from 10 to 35mg/ml, from 10 to 30mg/ml, from 8 to 22mg/ml, from 10 to 22mg/ml, from 15 to 22mg/ml, from 10 to 20mg/ml, from 6 to 25mg/ml or from 10 to 25mg/ml and sufficient methanesulphonic acid and 2-hydroxypropyl-beta-cyclodextrin are present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, methanesulphonic acid, sulphobutylether-p-cyclodextrin and water, wherein 1 -(4- {[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea is present at a solution concentration of less than 35mg/ml or up to 30mg/ml and sufficient methanesulphonic acid and sulphobutylether-β- cyclodextrin are present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea methanesulphonate, methanesulphonic acid, sulphobutylether-p-cyclodextrin and water, wherein 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6- dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea is present at a solution concentration of less than 35mg/ml or up to 30mg/ml and sufficient methanesulphonic acid and sulphobutylether-p-cyclodextrin are present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, methanesulphonic acid, sulphobutylether-p-cyclodextrin and water, wherein 1 -(4- {[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea is present at a solution concentration of from 6 to 30mg/ml, from 8 to 30mg/ml, from 10 to 30mg/ml, from 8 to 22mg/ml, from 10 to 22mg/ml, from 15 to 22mg/ml, from 10 to 20mg/ml, from 6 to 25mg/ml or from 10 to 25mg/ml and sufficient methanesulphonic acid and sulphobutylether-p-cyclodextrin are present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea methanesulphonate, methanesulphonic acid, sulphobutylether-p-cyclodextrin and water, wherein 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6- dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea is present at a solution concentration of from 6 to 30mg/ml, from 8 to 30mg/ml, from 10 to 30mg/ml, from 8 to 22mg/ml, from 10 to 22mg/ml, from 15 to 22mg/ml, from 10 to 20mg/ml, from 6 to 25mg/ml or from 10 to 25mg/ml and sufficient methanesulphonic acid and sulphobutylether-β- cyclodextrin are present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, methanesulphonic acid, gamma-cyclodextrin and water, wherein 1 -(4-{[4- (dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea is present at a solution concentration of less than 35mg/ml or up to 30mg/ml and sufficient methanesulphonic acid and gamma-cyclodextrin are present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea methanesulphonate, methanesulphonic acid, gamma-cyclodextrin and water, wherein 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6- dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea is present at a solution concentration of less than 35mg/ml or up to 30mg/ml and sufficient methanesulphonic acid and gamma-cyclodextrin are present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, methanesulphonic acid, gamma-cyclodexthn and water, wherein 1 -(4-{[4- (dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea is present at a solution concentration of from from 6 to 30mg/ml, from 8 to 30mg/ml, from 10 to 30mg/ml, from 8 to 22mg/ml, from 10 to 22mg/ml, from 15 to 22mg/ml, from 10 to 20mg/ml, from 6 to 25mg/ml or from 10 to 25mg/ml and sufficient methanesulphonic acid and gamma-cyclodexthn are present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea methanesulphonate, methanesulphonic acid, gamma-cyclodexthn and water, wherein 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6- dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea is present at a solution concentration of from 6 to 30mg/ml, from 8 to 30mg/ml, from 10 to 30mg/ml, from 8 to 22mg/ml, from 10 to 22mg/ml, from 15 to 22mg/ml, from 10 to 20mg/ml, from 6 to 25mg/ml or from 10 to 25mg/ml and sufficient methanesulphonic acid and gamma-cyclodexthn are present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, ethanesulphonic acid, 2-hydroxypropyl-beta-cyclodextrin and water, wherein 1 -(4- {[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea is present at a solution concentration of less than 40mg/ml or up to 35mg/ml and sufficient ethanesulphonic acid and 2-hydroxypropyl-beta- cyclodextrin are present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea ethanesulphonate, ethanesulphonic acid, 2-hydroxypropyl-beta-cyclodextrin and water, wherein 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6- dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea is present at a solution concentration of less than 40mg/ml or up to 35mg/ml and sufficient ethanesulphonic acid and 2- hydroxypropyl-beta-cyclodextrin are present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, ethanesulphonic acid, 2-hydroxypropyl-beta-cyclodextrin and water, wherein 1 -(4- {[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea is present at a solution concentration of up to 30mg/ml, from 6 to 30mg/ml, from 8 to 30mg/ml, from 10 to 35mg/ml, from 10 to 30mg/ml, from 8 to 22mg/ml, from 10 to 22mg/ml, from 15 to 22mg/ml, from 10 to 20mg/ml, from 6 to 25mg/ml or from 10 to 25mg/ml and sufficient ethanesulphonic acid and 2- hydroxypropyl-beta-cyclodextrin are present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea ethanesulphonate, ethanesulphonic acid, 2-hydroxypropyl-beta-cyclodextrin and water, wherein 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6- dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea is present at a solution concentration of up to 30mg/ml, from 6 to 30mg/ml, from 8 to 30mg/ml, from 10 to 35mg/ml, from 10 to 30mg/ml, from 8 to 22mg/ml, from 10 to 22mg/ml, from 15 to 22mg/ml, from 10 to 20mg/ml, from 6 to 25mg/ml or from 10 to 25mg/ml and sufficient ethanesulphonic acid and 2-hydroxypropyl-beta-cyclodextrin are present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, ethanesulphonic acid, sulphobutylether-p-cyclodextrin and water, wherein 1 -(4-{[4- (dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea is present at a solution concentration of less than 40mg/ml or up to 35mg/ml and sufficient ethanesulphonic acid and sulphobutylether-β- cyclodextrin are present to provide a clear solution. One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea ethanesulphonate, ethanesulphonic acid, sulphobutylether-p-cyclodextrin and water, wherein 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6- dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea is present at a solution concentration of less than 40mg/ml or up to 35mg/ml and sufficient ethanesulphonic acid and sulphobutylether-p-cyclodextrin are present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, ethanesulphonic acid, sulphobutylether-p-cyclodextrin and water, wherein 1 -(4-{[4- (dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea is present at a solution concentration of up to 30mg/ml, from 6 to 30mg/ml, from 8 to 30mg/ml, from 10 to 30mg/ml, from 8 to 22mg/ml, from 10 to 22mg/ml, from 15 to 22mg/ml, from 10 to 20mg/ml, from 6 to 25mg/ml or from 10 to 25mg/ml and sufficient ethanesulphonic acid and sulphobutylether-p-cyclodextrin are present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea ethanesulphonate, ethanesulphonic acid, sulphobutylether-p-cyclodextrin and water, wherein 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6- dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea is present at a solution concentration of up to 30mg/ml, from 6 to 30mg/ml, from 8 to 30mg/ml, from 10 to 30mg/ml, from 8 to 22mg/ml, from 10 to 22mg/ml, from 15 to 22mg/ml, from 10 to 20mg/ml, from 6 to 25mg/ml or from 10 to 25mg/ml and sufficient ethanesulphonic acid and sulphobutylether-p-cyclodextrin are present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, ethanesulphonic acid, gamma-cyclodextrin and water, wherein 1 -(4-{[4- (dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea is present at a solution concentration of less than 25mg/ml or up to 20mg/ml and sufficient ethanesulphonic acid and gamma-cyclodextrin are present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea ethanesulphonate, ethanesulphonic acid, gamma-cyclodextrin and water, wherein 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl- 1 ,3,5-triazin-2-yl)phenyl]urea is present at a solution concentration of less than 25mg/ml or up to 20mg/ml and sufficient methanesulphonic acid and gamma- cyclodextrin are present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea, ethanesulphonic acid, gamma-cyclodextrin and water, wherein 1 -(4-{[4- (dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea is present at a solution concentration of from 6 to 20mg/ml, from 8 to 20mg/ml, from 10 to 20mg/ml, from 8 to 15mg/ml, or from 15 to 20mg/ml and sufficient ethanesulphonic acid and gamma-cyclodextrin are present to provide a clear solution.

One embodiment of the formulation of the invention provides a pharmaceutical aqueous solution formulation comprising 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea ethanesulphonate, ethanesulphonic acid, gamma-cyclodextrin and water, wherein 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl- 1 ,3,5-triazin-2-yl)phenyl]urea is present at a solution concentration of from 6 to 20mg/ml, from 8 to 20mg/ml, from 10 to 20mg/ml, from 8 to 15mg/ml, or from 15 to 20mg/ml and sufficient ethanesulphonic acid and gamma-cyclodextrin are present to provide a clear solution. The preferred concentration of methanesulphonic acid or ethanesulphonic acid for use in a formulation of the invention is from 10 to 200mM, 20 to 200mM, 30 to 200mM or from 50 to 200mM, and preferably is about 50mM, about 100mM or about 150mM. Preferably, the concentration of methanesulphonic acid or

ethanesulphonic acid is about 100mM. Preferably, about a 100mM concentration of methanesulphonic acid is used.

The preferred amount of pharmaceutically acceptable beta- or gamma- cyclodextrin for use in a formulation of the invention is from 2 to 30% w/v, 3 to 20% w/v, from 5 to 20% w/v or from 15 to 30% w/v, and preferably is about 20% w/v or 25% w/v. Preferably, the amount of pharmaceutically acceptable beta- or gamma- cyclodextrin for use in a formulation of the invention is about 20% w/v. If the formulation of the invention is to be freeze-dried to provide a lyophilised solid composition, a bulking agent may be added to the formulation prior to the freeze-drying process commencing. A bulking agent may not be present if the formulation of the invention contains a pharmaceutically acceptable beta- or gamma- cyclodextrin. The primary function of the bulking agent is to provide the freeze-dried solid with a non-collapsible, structural integrity that will allow rapid reconstitution on constitution of the aqueous formulation prior to administration, and it should also facilitate efficient lyophilisation. Bulking agents are typically used when the total mass of solutes in the formulation is less than 2g/100ml. Bulking agents may also be added to achieve isotonicity with blood. The bulking agent may be selected from a saccharide, sugar alcohol, amino acid or polymer, or be a mixture of two or more of any thereof. Preferably, the bulking agent is a sugar or sugar alcohol, or a mixture thereof. Preferably, the sugar is sucrose. Preferably, the sugar alcohol is mannitol.

Preferably, from 5 to10% w/v of a bulking agent is used, if present . Reconstitution of the lyophilised solid composition may be achieved by addition of the requisite quantity of water that was present prior to lyophilisation in order that a clear solution is obtained. A tonicity modifier may then be added prior to use.

Constitution of the lyophilised solid composition may be achieved using an appropriate quantity of water and/or an aqueous solution of a suitable tonicity modifier in order to ensure that a clear solution is obtained.

A tonicity modifier may be present prior to intravenous or parenteral administration of the formulation to a patient by injection to avoid crenation or hemolysis of red blood cells, and to mitigate or avoid pain and discomfort to the patient. This requires that the formulation to be administered to the patient has an effective osmotic pressure that is approximately the same as that of the blood of the patient.

Suitable tonicity modifiers are non-ionic tonicity modifiers such as glycerol, sorbitol, mannitol, sucrose, propylene glycol or dextrose, or a mixture of any 2 or more thereof. Preferably the non-ionic tonicity modifier is dextrose, sucrose or mannitol, or is a mixture of any 2 or more thereof

Preferably, from 1 to 5% w/v of a tonicity modifier is used.

Aqueous pharmaceutical formulations of the invention that are suitable for intravenous administration generally have a pH of from 3 to 9. However, lower pH values are tolerated in certain settings. Preferably, the pH is from 3 to 8 or from 4 to 8.

The formulation of the invention may be used for the curative, palliative or prophylactic treatment of cancer in a mammal, including a human being. The cancer to be treated may be selected from the group consisting of leukemia, skin cancer, bladder cancer, breast cancer, uterus cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer and brain cancer.

The weekly dose of 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-

[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea to be administered by the intravenous route for the treatment of cancer using the formulations disclosed herein is preferably in the range of from 100 to 400mg per week.

The following Figures illustrate the claimed invention:

Figure 1 : OPM micrographs of Example 5B containing 22mg/ml of 1 -(4-{[4- (dimethylamino)piperidin-l -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea in 100mM ESA

Figure 2: OPM micrographs of Example 5A containing 22mg/ml of 1 -(4-{[4- (dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea in 100mM MSA

Figure 3: re. European Pharmacopoeia Method 2.9.20: "Figure 2.9.20.-1. - Apparatus for visible particles"

The following Examples describe the preparation of the formulations of the invention.

EXAMPLE 1

Preparation of a pharmaceutical aqueous solution formulation comprising 22mq /ml of 1 -(4-{r4-(dimethylamino)piperidin-1 -yl1carbonyl)phenyl)-3-r4-(4,6-dimorpholin-4-yl- 1 ,3,5-triazin-2-yl)phenyl1urea and methanesulfonic acid Methanesulfonic acid (99% w/w purity) (0.65 ml) was dissolved in water for irrigation (80ml). 1 -(4-{[4-(Dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6- dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea (220mg) was added to the solution and stirred until a particle-free solution was achieved. Water for irrigation was added with stirring to achieve a target volume of 100ml.

(i) Visual analysis

A sample of the formulation was analysed in accordance with the visual method defined in European Pharmacopoeia Method 2.9.20 (using a Verivide (trade mark) light cabinet and a light meter reading of 3250 lux against a matt black panel and a white panel) to determine if crystallites or particles were present. The sample was tested by this method both when the solution was first made up and then 24 hours thereafter.

(ii) OPM analysis

A sample of the formulation was placed on a clean glass microscopy slide and covered with a glass cover slip. It was then analysed by OPM using both nonpolarised and cross-polarised light under a Nikon LV 100POL (trade mark) microscope with a 10x magnification lens and a 10x magnification eyepiece to determine if crystallites or particles were present. The image was recorded using a DFK 23UP031 TIS USB 3.0 CMOS (trade mark) Colour Industrial Camera 5MP 1/2,5" and image capture software. The procedure was also repeated using a sample of the formulation in a glass capillary tube. The sample was tested by this method when the solution was first made up, and then at 4 and 24 hours thereafter.

EXAMPLE 2

Preparation of a pharmaceutical aqueous solution formulation comprising 22mq /ml of 1 -(4-{[4-(dimethylamino)piperidin-1 -yl1carbonyl)phenyl)-3-[4-(4,6-dimorpholin-4-yl- 1 ,3,5-triazin-2-yl)phenyl1urea and ethanesulfonic acid

Ethanesulfonic acid (70% w/v) (3144.7microl_), was diluted with water for irrigation (80ml). 1 -(4-{[4-(Dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6- dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea (220mg) was added to the solution and stirred until a particle-free solution was achieved. Water for irrigation was added with stirring to achieve target volume of 100ml.

Samples of the formulation were analysed in accordance with the methods of Example 1 .

EXAMPLE 3

Preparation of (a) a pharmaceutical aqueous solution formulation comprising 22mq /ml of 1 -(4-{r4-(dimethylamino)piperidin-1 -yl1carbonyl)phenyl)-3-r4-(4,6-dimorpholin- 4-yl-1 ,3,5-thazin-2-yl)phenyl1urea, methanesulfonic acid and mannitol; and (b) a lyophilised composition thereof.

(a) Methanesulfonic acid (99% w/w purity) (0.65 ml) was dissolved in water for irrigation (80ml). Mannitol (2.8g) was dissolved in this buffer solution by stirring to achieve total dissolution. 1 -(4-{[4-(Dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea (220mg) was added to the solution and stirred until a particle-free solution was achieved. Water for irrigation was added with stirring to achieve a target volume of 100ml. Samples of the formulation were analysed in accordance with the methods of Example 1.

(b) The formulation from (a) was filled into 10 mL vials to a target volume of 3 ml.

The vials were partially stoppered (not sealed) with a 20mm Gray Lyo D777-1

V10-F597W FluroTec Siliconised (trade mark) stopper. The vials were loaded into stainless steel trays and inserted into a LSL1000 (trade mark) freeze dryer. The shelf temperature was set at 5°C. The freeze drying cycle was run using the tabulated method below.

The freeze dryer was back-filled with sterile filtered nitrogen to a set point of 500 Torr (ca. 666mbar or 66,600 Pascals), and the vials were fully closed using the stoppers. The freeze dryer was then vented to atmospheric pressure using sterile filtered air and the vials were unloaded from the freeze dryer.

Each vial contained the freeze dried (lyophilised) formulation as an off-white solid.

EXAMPLE 4

Preparation of (a) a pharmaceutical agueous solution formulation comprising 22mg /ml of 1 -(4-{r4-(dimethylamino)piperidin-1-yl1carbonyl)phenyl)-3-r4- (4,6-dimorpholin- 4-yl-1 ,3,5-thazin-2-yl)phenyl1urea, ethanesulfonic acid and mannitol; and (b) a lyophilised composition thereof.

(a) Ethanesulfonic acid (70% w/v) (3144.7microl_), was diluted with water for irrigation (80ml). Mannitol (2.8g) was dissolved in the buffer solution and stirred to achieve total dissolution. 1-(4-{[4-(Dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea (220mg) was added to the solution and stirred until a particle-free solution was achieved. Water for irrigation was added with stirring to achieve target volume of 100ml.

Samples of the formulation were analysed in accordance with the methods of Example 1.

(b) The formulation from (a) was filled into 10 mL vials to a target volume of 3 ml. The vials were partially stoppered (not sealed) with a 20mm Gray Lyo D777-1 V10-F597W FluroTec Siliconised (trade mark) stopper. The vials were loaded into stainless steel trays and inserted into a LSL1000 (trade mark) freeze dryer. The shelf temperature was set at 5°C. The freeze drying cycle was run using the tabulated method below. Tim

Temperatur e

e (degrees (min Temperature change

Condition Rate/Hold C) ■) (degrees C) per minute Pressure

760 Torr (1

Loading Hold 5 n/a n/a Atmosphere)

760 Torr (1

Stabilisation Hold 5 120 n/a Atmosphere)

760 Torr (1

Rate -40 480 0.1 deg. C/min Atmosphere)

760 Torr (1

Freeze Hold -40 180 n/a Atmosphere)

760 Torr (1

Rate -12 280 0.1 deg. C/min Atmosphere)

760 Torr (1

Annealing Hold -12 180 n/a Atmosphere)

760 Torr (1

Cooling Rate -40 280 0.1 deg. C/min Atmosphere)

Evacuation Hold -40 100 n/a 90 mTorr

Hold -40 30 n/a 90 mTorr

Primary Rate -30 100 0.5 deg. C/min 90 mTorr Drying Hold -30 5450 n/a 90 mTorr

Rate 20 500 0.5 deg. C/min 90 mTorr

Hold 20 500 n/a 90 mTorr

Secondary Rate 40 200 0.5 deg. C/min 90 mTorr Drying Hold 40 500 n/a 90 mTorr

The freeze dryer was back-filled with sterile filtered nitrogen to a set point of 500 Torr (ca. 666mbar or 66,600 Pascals), and the vials were fully closed using the stoppers. The freeze dryer was then vented to atmospheric pressure using sterile filtered air and the vials were unloaded from the freeze dryer.

Each vial contained the freeze dried (lyophilised) formulation as an off-white solid.

EXAMPLE 5A

Reconstitution of a pharmaceutical aqueous solution formulation comprising 22mq

/ml of 1 -(4-{r4-(dimethylamino)piperidin-1-yl1carbonyl)phenyl)-3-r4- (4,6-dimorpholin- 4-yl-1 ,3,5-thazin-2-yl)phenyl1urea, methanesulfonic acid and mannitol from a lyophilised solid composition

A vial of lyophilised solid composition prepared in Example 3(b) was reconstituted as follows.

Water for irrigation (3ml) was injected using a syringe into the vial containing the lyophilised composition prepared in Example 3(b). The mixture was swirled until a particle-free solution was obtained.

The reconstituted formulation was analysed in accordance with the methods of Example !

Figure 2 shows OPM micrographs taken immediately after reconstitution at 100x magnification. There was no evidence of any particulate or crystalline material within the sample.

EXAMPLE 5B

Reconstitution of a pharmaceutical aqueous solution formulation comprising 22mq

/ml of 1 -(4-{[4-(dimethylamino)piperidin-1 -yl1carbonyl)phenyl)-3-[4-(4,6-dimorpholin- 4-yl-1 ,3,5-triazin-2-yl)phenyl1urea, ethanesulfonic acid and mannitol from a lyophilised solid composition

A vial of lyophilised solid composition prepared in Example 4(b) was reconstituted as follows.

Water for irrigation (3ml) was injected using a syringe into the vial containing the lyophilised composition prepared in Example 4(b). The mixture was swirled until a particle-free solution was obtained.

The reconstituted formulation was analysed in accordance with the methods of Example 1 .

Figure 1 shows OPM micrographs taken immediately after reconstitution at

100x magnification . There is no evidence of any particulate or crystalline material within the sample. The opalescence of the solution that was observed is likely due to the presence of a chromonic liquid crystal phase.

EXAMPLES 6-18

Examples 6-18 were prepared in accordance with the method of the relevant Example 1 , 2, 3(a) or 4(a) using the ingredient specification tabulated below.

MSA = methanesulphonic acid

ESA = ethanesulphonic acid

API = 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin- 4-yl-1 ,3,5-triazin-2-yl)phenyl]urea EXAMPLE 19

Preparation of a pharmaceutical aqueous solution formulation comprising 35mq /ml of 1 -(4-{[4-(dimethylamino)piperidin-1 -yl1carbonyl)phenyl)-3-[4-(4,6-dimorpholin-4-yl- 1 ,3,5-triazin-2-yl)phenyl1urea, 20% w/v 2-hvdroxypropyl-beta-cvclodextrin and methanesulfonic acid

Methanesulfonic acid (99% w/w purity) (0.65 ml, 100mM) was dissolved in water for irrigation (80ml). 2-Hydroxypropyl-beta-cyclodextrin (93% w/w adjusted potency) (21 .57g, 14.72mM) was added and the solution was stirred until a particle- free solution was achieved. 1 -(4-{[4-(Dimethylamino)piperidin-1 -yl]carbonyl}phenyl)- 3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea (350mg, 0.56mM) was added to the solution and stirred until a particle-free solution was achieved. Water for irrigation was added with stirring to achieve a target volume of 100ml.

Samples of the formulation were analysed in accordance with the methods of Example 1 .

EXAMPLE 20

Preparation of a pharmaceutical aqueous solution formulation comprising 35mq /ml of 1 -(4-{r4-(dimethylamino)piperidin-1 -yl1carbonyl)phenyl)-3-r4-(4,6-dimorpholin-4-yl- 1 ,3,5-triazin-2-yl)phenyl1urea, ethanesulfonic acid and 20% w/v 2-hydroxypropyl- beta-cyclodextrin

Ethanesulfonic acid (70% w/v) (3144.7microl_, 100mM) was diluted with water for irrigation (80ml). 2-Hydroxypropyl-beta-cyclodextrin (93% w/w adjusted potency) (21 .57g, 14.72mM) was added and the solution was stirred until a particle-free solution was achieved. 1 -(4-{[4-(Dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4- (4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea (350mg, 0.56mM) was added to the solution and stirred until a particle-free solution was achieved. Water for irrigation was added with stirring to achieve target volume of 100ml.

Samples of the formulation were analysed in accordance with the methods of Example 1 .

EXAMPLE 21

Preparation of a pharmaceutical aqueous solution formulation comprising 20mg /ml of 1 -(4-{r4-(dimethylamino)piperidin-1 -yl1carbonyl)phenyl)-3-r4-(4,6-dimorpholin-4-yl- 1 ,3,5-thazin-2-yl)phenyl1urea, ethanesulfonic acid and 20% w/v gamma-cyclodextrin

Ethanesulfonic acid (70% w/v) (3144.7microl_, 100mM) was diluted with water for irrigation (80ml). Gamma-cyclodextrin (assumed 100% potency) (20g, 15.4mM) was added and the solution was stirred until a particle-free solution was achieved. 1 - (4-{[4-(Dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl- 1 ,3,5-triazin-2-yl)phenyl]urea (200mg, 0.32mM) was added to the solution and stirred until a particle-free solution was achieved. Water for irrigation was added with stirring to achieve target volume of 100ml.

Samples of the formulation were analysed in accordance with the methods of Example 1 .

EXAMPLE 22

Preparation of a pharmaceutical aqueous solution formulation comprising 30mq /ml of 1 -(4-{[4-(dimethylamino)piperidin-1 -yl1carbonyl)phenyl)-3-[4-(4,6-dimorpholin-4-yl- 1 ,3,5-triazin-2-yl)phenyl1urea, methanesulfonic acid and 20% w/v sulphobutylether- 3-cvclodextrin (SBECD)

Methanesulfonic acid (99% w/w purity) (0.65 ml, 100mM) was dissolved in water for irrigation (80ml). Sulphobutylether-p-cyclodextrin (SBECD) (93% w/w adjusted potency) (21 .57g, 9.62mM) was added and the solution was stirred until a particle free solution was achieved. 1 -(4-{[4-(Dimethylamino)piperidin-1 -yl]carbonyl}phenyl)- 3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea (300mg, 0.48mM) was added to the solution and stirred until a particle-free solution was achieved. Water for irrigation was added with stirring to achieve a target volume of 100ml.

Samples of the formulation were analysed in accordance with the methods of Example 1 .

EXAMPLE 23

Preparation of a pharmaceutical aqueous solution formulation comprising 30mq /ml of 1 -(4-{r4-(dimethylamino)piperidin-1 -yl1carbonyl)phenyl)-3-r4-(4,6-dimorpholin-4-yl- 1 ,3,5-triazin-2-yl)phenyl1urea, methanesulfonic acid and 20% w/v gamma- cyclodextrin

Methanesulfonic acid (99% w/w purity) (0.65 ml, 100mM) was diluted with water for irrigation (80ml). Gamma-cyclodextrin (assumed 100% potency) (20g, 15.42mM) was added and the solution was stirred until a particle-free solution was achieved. 1 -(4-{[4-(Dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6- dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea (300mg, 0.48mM) was added to the solution and stirred until a particle-free solution was achieved. Water for irrigation was added with stirring to achieve target volume of 100ml. Samples of the formulation were analysed in accordance with the methods of

Example 1.

FURTHER EXAMPLES of the preparation of pharmaceutical aqueous solution formulations comprising 1-(4-IT4-(dimethylamino)piperidin-1- vncarbonyl>phenyl)-3-r4-(4,6-climorpholin-4-yl-1,3,5-tria zin-2-yl)phenvnurea, a beta- or qamma-cyclodextrin and methanesulfonic or ethanesulfonic acid

The following, tabulated Examples (indicated by a tick "V" or cross "x" in the Table) (target volume = 100ml) were prepared in accordance with the method of the relevant Example 19, 20, 21 , 22, 23 using the ingredient specification tabulated below.

These Examples were analysed by the visual method defined in European

Pharmacopoeia Method 2.9.20 and the OPM method both as described in Example 1. The results are also tabulated below.

In this Table " article-free" means that the the formulation was visually clear and free of visible crystallites or particulates, and "opalescent' means that the the formulation had an opalescence that is thought to result from the formation of a chromonic liquid crystal phase.

Key

MSA = methanesulphonic acid

ESA = ethanesulphonic acid

API = 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin

4-yl-1 ,3,5-triazin-2-yl)phenyl]urea

HPBCD = 2-hydroxypropyl-beta-cyclodextrin

AlphaCD = alpha-cyclodextrin

SBECD = sulphobutylether-p-cyclodextrin

GammaCD = gamma-cyclodextrin

(1) = particle-free (and non-opalescent). All these Examples studied are free of visible crystallite or particulate matter and meet the required "clear solution" definition as described earlier (n.b. they are indicated in the Table by not being darkly shaded).

(2) = particulate, opalescent

(3) = particulate suspension

EXAMPLE 24

Preparation of (a) a pharmaceutical aqueous solution formulation comprising 20mq /ml of 1 -(4-{r4-(dimethylamino)piperidin-1 -yl1carbonyl)phenyl)-3-r4-(4,6-dimorpholin- 4-yl-1 ,3,5-thazin-2-yl)phenyl1urea, methanesulfonic acid and 20% w/v 2- hvdroxypropyl-beta-cvclodextrin; and (b) a lyophilised composition thereof

(a) Methanesulfonic acid (99% w/w purity) (0.336 ml) (35mM) was dissolved in water for irrigation (80ml). 2-Hydroxypropyl-beta-cyclodextrin (21 .57g, 14.72mM) was dissolved in this buffer solution by stirring to achieve total dissolution. 1 -(4-{[4- (Dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5- triazin-2-yl)phenyl]urea (200mg, 0.325mM) was added to the solution and stirred until a particle-free solution was achieved. Water for irrigation was added with stirring to achieve a target volume of 100ml.

(b) The formulation from (a) was filled into 10 ml_ vials to a target volume of 3 ml. The vials were partially stoppered (not sealed) with a 20mm Gray Lyo D777-1 V10- F597W FluroTec Siliconised (trade mark) stopper. The vials were loaded into stainless steel trays and inserted into a LSL1000 (trade mark) freeze dryer. The shelf temperature was set at 25°C. The freeze drying cycle was run using the tabulated method below.

TemperaTime Temperature change Pressure

Condition Rate/Hold

ture (°C) (Minutes) (°C/minute) (mbar)

Loading Hold 25 n/a n/a 1 Atmosphere*

Stabilisation Hold 25 120 n/a 1 Atmosphere*

Freeze Rate -25 500 0.1 1 Atmosphere*

Hold -25 180 n/a 1 Atmosphere*

Rate -40 150 0.1 1 Atmosphere*

Hold -40 150 n/a 1 Atmosphere*

Evacuation Hold -40 n/a n/a 75 mTorr

Primary Drying Rate -15 112 0.5 75 mTorr

Hold -15 5810 n/a 75 mTorr

Secondary

Rate 0 150 0.1 75 mTorr Drying

Hold 0 480 n/a 75 mTorr

Rate 40 400 0.1 75 mTorr

Hold 40 480 n/a 75 mTorr

Rate 25 150 0.1 75 mTorr

Stoppering Hold 25 n/a n/a 500 Torr

Storage Hold 25 n/a n/a

(*760Torr)

The freeze dryer was back-filled with sterile filtered nitrogen to a set point of 500 Torr (ca. 666mbar or 66,600 Pascals), and the vials were fully closed using the stoppers. The freeze dryer was then vented to atmospheric pressure using sterile filtered air and the vials were unloaded from the freeze dryer.

Each vial contained the freeze dried (lyophilised) formulation as an off-white solid.

Analysis of Examples 1-18

The Examples shown in the following Table were analysed by the visual method defined in European Pharmacopoeia Method 2.9.20 and the OPM method both as described in Example 1. The results are tabulated below.

Further, the formulations of Examples 1 , 2 and 6-18 were each lyophilised by the same method used in Examples 3(b) and 4(b) and then each reconstituted by the same method as used in Examples 5A and 5B.

In this Table " article-free" means that the the formulation was visually clear and free of visible crystallites or particulates, and "opalescent, particle-free" means that the the formulation was free of visible crystallites or particulates but had a solution opalescence that is thought to result from the formation of a chromonic liquid crystal phase. There are Examples shown where the opalescence disappears on reconstitution of the formulation following lyophilisation. All Examples studied are free of visible crystallite or particulate matter and meet the required "clear solution" definition as described earlier.

Analysis for

Analysis

formulation for

API API Acid mannitol obtained after

Acid Example formulation

(mg/ml) (mg) (mM) (mg) reconstitution prepared in

following Example

lyophilisation opalescent,

1 22 2200 100 0 particle-free particle-free

opalescent,

3(a) 22 2200 100 2800 - particle-free

5A - particle-free

6 8 800 100 4200 particle-free particle-free

7 10 1000 100 4000 particle-free particle-free opalescent, particle-free

8 13 1300 100 3700

particle-free

opalescent, particle-free

9 15 1500 100 3500

particle-free

MSA opalescent, particle-free

10 15 1500 100 0

particle-free

opalescent, particle-free

1 1 30 3000 100 2000

particle-free

opalescent, opalescent,

12 30 3000 100 0

particle-free particle-free opalescent, opalescent,

13 ¹ 40 4000 100 1000

particle-free particle-free opalescent, opalescent,

14 ¹ 40 4000 100 0

particle-free particle-free opalescent, opalescent,

15 20 2000 50 3000

particle-free particle-free opalescent, opalescent,

2 22 2200 100 0

particle-free particle-free opalescent,

4(a) 22 2200 100 2800 - particle-free

opalescent,

5B -

ESA particle-free opalescent, opalescent,

16 30 3000 100 2000

particle-free particle-free opalescent,

17 20 2000 50 3000 particle-free particle-free

18 10 1000 100 4000 particle-free particle-free

Footnote

1 . Although this formulation meets the "clear solution" criterion, it is unsuitable for the intended purpose since it is a viscous solution that reconstitutes very slowly Key

MSA = methanesulphonic acid

ESA = ethanesulphonic acid

API = 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin- 4-yl-1 ,3,5-triazin-2-yl)phenyl]urea

Chemical stability of a lyophilised solid formulations of the invention

Two Samples of lyophilised formulations of the invention were prepared.

• Sample A was prepared by a similar procedure to that of Example 3 except that 2000mg of 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4- (4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea (i.e. 20mg/ml), 100mM of methanesulfonic acid (0.65ml) and 3000mg of mannitol were used to prepare the lyophile.

• Sample B was prepared by a similar procedure to that of Example 4 except that 2000mg of 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4- (4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea (i.e. 20mg/ml), 100mM of ethanesulfonic acid and 3000mg of mannitol were used to prepare the lyophile.

Separate portions of Samples A and B were each housed in 10 mL clear vials and were stored at 25°C/60% Relative Humidity ("RH"), 40°C/75% RH or 5°C for 6 weeks.

After 6 weeks storage as above, the Samples were each tested for chemical purity using Ultra High Performance Liquid Chromatography (UHPLC) using the following methodology in order to measure any chemical degradation during the period of testing.

UHPLC method The solutions, samples, standards and UHPLC method are as below: Reference Standard: 1 -(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3- [4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea with a known potency value.

Diluent: Acetonitrile/Water/Trifluoroacetic acid (750:250: 1 v/v/v)

Mobile Phase A: Acetonitrile/Water/Thfluoroacetic acid (97:3: 1 v/v/v)

Mobile Phase B: Acetonitrile/ Trifluoroacetic acid (1000: 1 v/v). (Note: larger or smaller volumes of solutions may be prepared using the appropriate ratio of components)

Standard and Check standard preparations:

• Accurately prepare two solutions of ca. 0.2 mg/ml_ (+/- 10%) of 1 -(4-{[4- (dimethylamino) piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-

1 ,3,5-triazin-2-yl)phenyl]urea Reference Standard in Diluent, and record the concentrations accurately of both. These are the Standard and Check standard preparations.

Sensitivity solution:

· Accurately dilute the Standard preparation to a concentration of

approximately 0.1 microgram/ml of 1 -(4-{[4-(dimethylamino)piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea using the Diluent. Sample preparation:

• Reconstitute Sample A or B after storage by adding 3.0 ml of water to each in the 10ml vial, shake the vial to dissolve the solid and wait for the bubbles to disappear. Transfer 1 .0ml of the solution into a 100ml volumetric flask. Dilute to the set volume with Diluent. Chromatographic conditions:

• Liquid chromatographic system -Agilent 1290 Infinity II™ with 380μΙ Jet Weaver™

• Column: Waters BEH C18™15 cm x 2.1 mm, 1.7 pm or equivalent

• Column Temperature: 20°C

• Injection Volume: 2 L

• Flow Rate: 0.25 mL /min.

• Flow Cell: G4212-60008, 10mm path length, 1.0μΙ_

• Detection: UV at 240 nm / 4nm slit width

• Run Time: 77 minutes

• Mobile Phase A

• Mobile Phase B

• Needle wash solution: Water / Acetonitrile (95:5 v/v), multi wash 20s.

• Seal wash solution: Water / Propan-2-ol (90: 10 v/v)

Linear Gradient Table:

Explanatory notes

Condition the UHPLC system, prior to starting the analysis, with the mobile phases. Prior to running samples, ensure that the system is suitable for use by injecting blank diluent, sensitivity solution and standard preparation using the

chromatographic conditions above.

The following criteria must be satisfied on initial UHPLC set-up or after any significant change to the system. It is recommended to inject at least one

conditioning blank prior to testing system suitability.

Test # of Solution Criteria

Injections

Blank 1 Diluent Chromatogram similar to Figures 3 and 4

Signal to 1 Sensitivity European Pharmacopoeia (EP)/United

Noise Solution States Pharmacopoeia (USP) Signal to

Noise > 10

Repeatability 5 Standard Relative Standard Deviation < 2.0%

Retention time 1* preparation 38-44 minutes

Efficiency Plate number for 1 -(4-{[4-

(Plate)** (dimethylamino)piperidin-l - yl]carbonyl}phenyl)-3-[4-(4,6- dimorpholin-4-yl-1 ,3,5-triazin-2- yl)phenyl]urea peak > 10,000

Peak 0.9 < T < 2.0 for i -(4-{[4-

Asymmetry (dimethylamino)piperidin-l - or yl]carbonyl}phenyl)-3-[4-(4,6- dimorpholin-4-yl-1 ,3,5-triazin-2- yl)phenyl]urea peak

Resolution 1 Resolution between 1-(4-{[4- (dimethylamino)piperidin-l - yl]carbonyl}phenyl)-3-[4-(4,6- dimorpholin-4-yl-1 ,3,5-triazin-2- yl)phenyl]urea peak and ((4-(4,6- dimorpholino-1 ,3,5-triazin-2-yl)phenyl)- l2-azaneyl)((4-(4-(methyl-l2- azaneyl)piperidine-1 -carbonyl)phenyl)-l2- azaneyl)methanone > 1 .0

* Use average of all system suitability (repeatability) injections.

** Refer to United States Pharmacopoeia (USP) calculation equations for Efficiency and Peak Asymmetry.

Inject the check standard preparation according to the chromatographic conditions above. The response factor (calculated from the area, standard weight, dilution factor and purity factor of the standard) of this check standard preparation must be within ± 2% of the standard preparation.

After the system suitability has been demonstrated, inject the blank solution, standard preparation and prepared test samples, followed by an injection of the standard preparation, according to the chromatographic conditions above. It is recommended that no more than 6 test samples be injected between standard preparation injections. For each injection (standard and sample), measure the retention time and area of the 1 -(4-{[4-(dimethylamino) piperidin-1 - yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]urea peak in each chromatogram. For each sample injection, also measure the retention times and peak area of any peaks present in the sample injection that do not appear in the blank injection. Do not integrate gradient artifacts, if present. Compare the blank injection chromatogram to the sample chromatogram to determine which peaks in the sample are related to the blank and gradient artifact peaks. Calculate the % w/w degradants and report the individual degradant peaks which are at or above 0.05% w/w. Unknown degradants should be reported individually by their relative retention time. Known degradants should be reported individually by name.

The results are summarised in the Tables below.

Key

• NMT = Not More Than.

• RRT = Relative Retention Time

• NO = Not Observed

Deqradant 1

Degradants 2. 3. 4. 5 and 6

These were each characterised by their RRT only.

Sample A results

Sample B results

5°C 25°C / 60% RH 40°C / 75% RH

Degradant 1 0.09 0.12 0.1 1

Degradant 2

NO 0.06 NO

RRT-1.150

Degradant 3

0.06 0.07 NMT 0.05 RRT-1.179

Degradant 4

NO NO NO RRT-1.185

Degradant 5

0.14 0.25 0.99 RRT-1.24

Degradant 6

0.08 0.08 0.08 RRT-1.324

Total

degradants 0.37 0.58 1.18 (w/w) Conclusion

The results show that Samples A and B are chemically stable for at least 6 weeks at 25°C/60% RH.